勃林格殷格翰能倍乐在哪里买？

Respimat (generic name: Tiotropium bromide/olodaterol, Spiolto® Respimat®) is a drug developed by Boehringer Ingelheim. It has been officially approved by the China Food and Drug Administration and is suitable for long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD, referred to as COPD, including chronic bronchitis and emphysema) to relieve symptoms. COPD is a long-term lung disease that causes shortness of breath and coughing. Helps open the airways, making it easier for air to move in and out of the lungs. Normal use of Respimat can also relieve persistent shortness of breath caused by the disease, helping to minimize the impact of the disease on daily life.

Boehringer Ingelheim is a leading global pharmaceutical company driven by research and development. In the three business areas of human pharmaceuticals, animal health and biopharmaceutical contract manufacturing, more than 51,000 employees around the world work hard to demonstrate value through innovation every day. In 2019, Boehringer Ingelheim achieved net sales of €19 billion and R&D expenditures of nearly €3.5 billion.

Where to buy Boehringer Ingelheim Respimat? According to Medical Partner Travel, in July 2018, Sihehua® Respimat® (tiotropium bromide/olodaterol inhalation spray) was officially approved by the China Food and Drug Administration for long-term maintenance treatment of patients with chronic obstructive pulmonary disease (including chronic bronchitis and emphysema). Patients can buy Boehringer Ingelheim in China, and it is currently included in the national medical insurance catalog and is a Class B drug in medical insurance. Although patients cannot be reimbursed in full when purchasing drugs, it can also reduce a certain financial burden for patients.

Recommended related hot articles: /newsDetail/97402.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.